{
}
CRISPR Therapeutics, trading at $39.69 with a market cap of $3.39 billion, is focusing on the launch of its gene-based medicine CASGEVY® and advancing its gene editing pipeline. The company reported operating expenses of $110.1 million and a cash position of $1.94 billion, while analysts hold mixed ratings. Key developments include ongoing clinical trials for CTX112™ and CTX131™, with updates expected in 2025, alongside a strong demand for CASGEVY® following its regulatory approval for sickle cell disease and beta thalassemia.
CRISPR Therapeutics is expanding its CTX112 trial to include patients with systemic sclerosis and inflammatory myositis, with updates expected in mid-2025. The company is also advancing its gene-edited CAR T therapy targeting GPC3 for solid tumors, with a clinical trial set to begin in early 2025. Additionally, significant progress is being made in cardiovascular gene editing and regenerative medicine, with multiple updates anticipated throughout 2025.
State Street Corp has increased its stake in CRISPR Therapeutics to nearly 3 million shares, valued at $140.6 million. CEO Samarth Kulkarni and General Counsel James R. Kasinger recently sold shares, reducing their holdings. Analysts maintain a "Hold" rating on the stock, with a consensus price target of $78.38.
CRISPR Therapeutics AG (CRSP) closed at $41.92, down 1.2%, underperforming the S&P 500's 1.11% loss. Over the past month, the stock has declined 14.87%, while the Medical sector lost 6.22%. The upcoming earnings report is expected to show an EPS of -$1.20 and revenue of $10.83 million, both significantly lower than last year. Currently, CRSP holds a Zacks Rank of #3 (Hold), with the Medical - Biomedical and Genetics industry ranked in the top 27% of over 250 industries.
CRISPR Therapeutics experienced a 1.86% decrease in insider ownership following recent stock sales totaling over $2.7 million. Institutional investors hold 69.20% of the company, with Bank of America lowering its price target to $85, indicating a potential upside of 100.61%. The stock currently has a "Hold" rating among analysts, with a consensus target price of $78.38.
Gene-editing stocks are poised for a rebound in 2025 after a tumultuous 2024. Vertex Pharmaceuticals' CRISPR-based treatment, Casgevy, showed a 93.5% effectiveness rate for sickle cell disease, while CRISPR Therapeutics and Intellia Therapeutics are advancing their pipelines with promising therapies for various genetic disorders. Both companies are expected to report significant developments in the coming year, with CRISPR Therapeutics targeting profitability by 2028 and Intellia leading in in vivo CRISPR-based medicines.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
Vertex Pharmaceuticals has entered a three-year partnership with Orna Therapeutics to advance in vivo gene therapies for sickle cell disease and beta thalassemia. The collaboration includes an upfront payment of $65 million, with potential milestone payments totaling up to $635 million. This initiative aims to enhance gene editing delivery methods, potentially eliminating the need for toxic preconditioning and streamlining the treatment process.
CRISPR Therapeutics has a consensus rating of "Hold" with a price target of $77.93, as analysts remain divided with two sell, eight hold, and nine buy ratings. The stock opened at $40.48, reflecting a market cap of $3.46 billion and a P/E ratio of -14.30. In its latest earnings report, the company beat EPS estimates but fell short on revenue, posting a loss of $1.01 per share against expectations of $1.42.
Crispr Therapeutics Ag (CRSP) is currently rated weak across all terms, with a buy recommendation near $35.21 targeting $43.04, and a stop loss at $35.11. A short position is advised near $43.04, targeting $35.21, with a stop loss at $43.16. If CRSP breaks above $43.04, a buy signal emerges with a target of $52.41.
CRISPR Therapeutics AG
Companies
| Symbol | CRSP |
| Name | CRISPR Therapeutics AG |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | Switzerland |
| State | |
| City | Zug |
| Zipcode | 6300 |
| Website | http://www.crisprtx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
CRISPR Therapeutics sets ambitious 2025 goals amid strong market presence
United States Dollar
Vertex Pharmaceuticals Inc
CRISPR Therapeutics AG
CHE
Briggs Morrison
Samarth Kulkarni
13:10 13.01.2025
crispr therapeutics advances gene editing therapies for various diseases
13:02 13.01.2025
state street increases stake in crispr therapeutics amid insider stock sales
13:18 09.01.2025
crispr therapeutics faces significant stock decline ahead of earnings report
00:00 08.01.2025
insider sales and institutional investments impact crisper therapeutics stock performance
19:33 07.01.2025
gene editing stocks poised for recovery with promising treatments in 2025
14:47 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
vertex partners with orna to advance in vivo gene editing therapies
01:00 07.01.2025
crispr therapeutics stock ratings and performance analysis update
09:55 24.12.2024
Crispr Therapeutics trading strategies and market signals for December 2024
08:52 24.12.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Venture Capital Investments
Fintech Startups
Cryptocurrency Trends
Emerging Startups
Funding Rounds & Investments
Retail and Consumer Goods
AI Innovations
Crypto Policies and Governance
Crypto Adoption and Integration
IPOs & SPACs
Economic Indicators
Product Launches
Market Analysis and Predictions
Private Equity Deals
Central Banks and Digital Currencies
Stock Market Updates
IPOs of Tech Companies
Countries:
Companies:
Nvidia Corporation
Apple Inc.
Microsoft Corporation Corp.
Amazon.com Inc.
Alphabet Inc.
DEUTSCHE BANK AG
Micelio Technology Fund 1
PayPal Holdings Inc.
Uber Technologies Inc.
Indifi Technologies Ltd.
The Goldman Sachs Group, Inc.
Axis Capital Ltd.
UBS Group AG
Reddit Inc.
Google LLC
Anduril Industries Inc.
Maruishi Pharmaceutical Co. Ltd.
Qatar Islamic Bank ش.م.ع
Walmart Inc.
Trump Media & Technology Group Corp.
Currencies:
People: